Evaluate’s 2026 Orphan Drugs Report projects global orphan drug sales surpassing $400 billion by 2032, driven by expanding portfolios at companies such as Johnson & Johnson and Vertex. The report highlights both commercial opportunity and headwinds, including FDA scrutiny on pricing and regulatory volatility despite policy wins like IRA exceptions and voucher reauthorizations. In parallel, the FDA’s Rare Disease Evidence Principles (RDEP) framework seeks to provide trial flexibility—encouraging use of real‑world data, natural history controls and biologically plausible endpoints to support accelerated approvals in small populations. Together, the market projection and regulatory guidance sketch a landscape where commercial upside collides with evolving evidentiary expectations and payor pressures, shaping strategy for rare‑disease sponsors and investors.